-

Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2025 financial results on Wednesday, November 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 5th, at 9:00 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Laboratories Announces Third-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2026 Results...

Charles River Leverages Virtual Control Groups in GLP Studies

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen....

Charles River, Labcorp, and FDA Collaborate to Validate New Preclinical Methods for Abuse Potential Assessment

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River announced a collaboration with the U.S. FDA and Labcorp to develop screening tools to quantify and rank the abuse potential of new drugs...
Back to Newsroom